Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Recommendation of “Hold” from Analysts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has earned a consensus rating of “Hold” from the twenty-eight analysts that are covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a sell recommendation, thirteen have given a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $33.56.

A number of research firms have recently issued reports on SRPT. Royal Bank Of Canada upped their target price on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the stock a “sector perform” rating in a report on Thursday, January 8th. Barclays initiated coverage on shares of Sarepta Therapeutics in a research report on Wednesday, January 28th. They set an “equal weight” rating and a $20.00 price target on the stock. Wells Fargo & Company dropped their price objective on shares of Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a research note on Friday. Weiss Ratings reissued a “sell (d)” rating on shares of Sarepta Therapeutics in a research note on Monday, December 29th. Finally, Mizuho upgraded Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $19.00 to $26.00 in a report on Wednesday, November 5th.

Insiders Place Their Bets

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the business’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total transaction of $294,201.97. Following the transaction, the chief operating officer owned 193,300 shares of the company’s stock, valued at approximately $4,312,523. The trade was a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of SRPT. Kestra Advisory Services LLC acquired a new position in shares of Sarepta Therapeutics during the 4th quarter valued at about $25,000. iSAM Funds UK Ltd acquired a new stake in shares of Sarepta Therapeutics during the third quarter valued at about $25,000. Ancora Advisors LLC raised its position in Sarepta Therapeutics by 200.0% in the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,000 shares during the period. Byrne Asset Management LLC acquired a new position in Sarepta Therapeutics during the third quarter worth $33,000. Finally, Allworth Financial LP lifted its stake in Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 1,721 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Key Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Revenue beat estimates in Q4 ($442.9M vs. ~$391M consensus), which partially offsets earnings weakness and suggests underlying commercial traction outside the challenged product. Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
• Positive Sentiment: Wells Fargo kept an “overweight” rating on SRPT, implying continued analyst conviction in the story despite lowering its price target to $38 (from $45), signaling potential upside from current levels. Wells Fargo Lowers Price Target
• Neutral Sentiment: Sarepta expanded non-market PR and community programs — opening applications for the Route 79 Duchenne scholarship — which supports brand and patient-community relations but is unlikely to move near-term valuation. Sarepta Announces Route 79 Scholarship
• Neutral Sentiment: Sarepta plans to present long-term and safety data at the upcoming MDA conference — data releases could be material but timing and contents are uncertain. Sarepta to Present Long-Term Data at MDA
• Negative Sentiment: Large Q4 EPS miss: reported EPS was far worse than consensus (reported loss −$3.58 vs. est. −$0.87), driven by a steep decline in ELEVIDYS sales and a wider net loss, increasing short-term revenue and margin uncertainty. Sarepta Q4 Earnings Report
• Negative Sentiment: CEO Douglas Ingram announced he will retire by year-end (or upon his replacement), introducing leadership transition risk at a sensitive time for product recovery and strategy execution. Reuters: Sarepta CEO Ingram to Retire
• Negative Sentiment: Institutional selling: AXQ Capital materially trimmed its SRPT stake (large percentage reduction), which can add selling pressure and signal reduced conviction among some holders. AXQ Capital Lowers Position in Sarepta

Sarepta Therapeutics Price Performance

Shares of Sarepta Therapeutics stock opened at $16.76 on Monday. The stock has a market capitalization of $1.76 billion, a P/E ratio of -1.99, a PEG ratio of 0.27 and a beta of 0.42. The business has a 50 day simple moving average of $20.43 and a two-hundred day simple moving average of $20.22. Sarepta Therapeutics has a 12 month low of $10.41 and a 12 month high of $108.48. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.32 and a quick ratio of 1.48.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71). Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The firm had revenue of $442.93 million during the quarter, compared to analyst estimates of $390.95 million. During the same period in the prior year, the firm earned $1.90 earnings per share. The business’s revenue was down 32.7% on a year-over-year basis. As a group, analysts predict that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.